Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: Implications for medication studies

Peter S. Jensen, Eric A. Youngstrom, Hans Steiner, Robert L. Findling, Roger Meyer, Richard P. Malone, Gabrielle A. Carlson, Emil F. Coccaro, Michael G. Aman, James Blair, Donald Dougherty, Craig Ferris, Laurie Flynn, Evelyn Green, Kimberly Hoagwood, Janice Hutchinson, Tom Laughren, Leslie D. Leve, Douglas K. Novins, Benedetto Vitiello

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

OBJECTIVE: To determine whether impulsive aggression (IA) is a meaningful clinical construct and to ascertain whether it is sufficiently similar across diagnostic categories, such that parallel studies across disorders might constitute appropriate evidence for pursuing indications. If so, how should IA be assessed, pharmacological studies designed, and ethical issues addressed? METHOD: Experts from key stakeholder communities, including academic clinicians, researchers, practicing clinicians, U.S. Food and Drug Administration, National Institute of Mental Health, industry sponsors, and patient and family advocates, met for a 2-day consensus conference on November 4 and 5, 2004. After evaluating summary presentations on current research evidence, participants were assigned to three workgroups, examined core issues, and generated consensus guidelines in their areas. Workgroup recommendations were discussed by the whole group to reach consensus, and then further iterated and condensed into this report postconference by the authors. RESULTS: Conference participants agreed that IA is a substantial public health and clinical concern, constitutes a key therapeutic target across multiple disorders, and can be measured with sufficient precision that pharmacological studies are warranted. Additional areas of consensus concerned types of measures, optimal study designs, and ethical imperatives. CONCLUSION: Derived from scientific evidence and clinical experience, these consensus-driven recommendations can guide the design of future studies. Copyright 2007

Original languageEnglish (US)
Pages (from-to)309-322
Number of pages14
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume46
Issue number3
DOIs
StatePublished - Mar 1 2007

Fingerprint

Child Psychiatry
Aggression
Consensus
Pharmacology
National Institute of Mental Health (U.S.)
United States Food and Drug Administration
Ethics
Industry
Public Health
Research Personnel
Guidelines
Research

All Science Journal Classification (ASJC) codes

  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Cite this

Jensen, Peter S. ; Youngstrom, Eric A. ; Steiner, Hans ; Findling, Robert L. ; Meyer, Roger ; Malone, Richard P. ; Carlson, Gabrielle A. ; Coccaro, Emil F. ; Aman, Michael G. ; Blair, James ; Dougherty, Donald ; Ferris, Craig ; Flynn, Laurie ; Green, Evelyn ; Hoagwood, Kimberly ; Hutchinson, Janice ; Laughren, Tom ; Leve, Leslie D. ; Novins, Douglas K. ; Vitiello, Benedetto. / Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry : Implications for medication studies. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2007 ; Vol. 46, No. 3. pp. 309-322.
@article{d34c0ee97a374bebae92fa36f3c11baf,
title = "Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: Implications for medication studies",
abstract = "OBJECTIVE: To determine whether impulsive aggression (IA) is a meaningful clinical construct and to ascertain whether it is sufficiently similar across diagnostic categories, such that parallel studies across disorders might constitute appropriate evidence for pursuing indications. If so, how should IA be assessed, pharmacological studies designed, and ethical issues addressed? METHOD: Experts from key stakeholder communities, including academic clinicians, researchers, practicing clinicians, U.S. Food and Drug Administration, National Institute of Mental Health, industry sponsors, and patient and family advocates, met for a 2-day consensus conference on November 4 and 5, 2004. After evaluating summary presentations on current research evidence, participants were assigned to three workgroups, examined core issues, and generated consensus guidelines in their areas. Workgroup recommendations were discussed by the whole group to reach consensus, and then further iterated and condensed into this report postconference by the authors. RESULTS: Conference participants agreed that IA is a substantial public health and clinical concern, constitutes a key therapeutic target across multiple disorders, and can be measured with sufficient precision that pharmacological studies are warranted. Additional areas of consensus concerned types of measures, optimal study designs, and ethical imperatives. CONCLUSION: Derived from scientific evidence and clinical experience, these consensus-driven recommendations can guide the design of future studies. Copyright 2007",
author = "Jensen, {Peter S.} and Youngstrom, {Eric A.} and Hans Steiner and Findling, {Robert L.} and Roger Meyer and Malone, {Richard P.} and Carlson, {Gabrielle A.} and Coccaro, {Emil F.} and Aman, {Michael G.} and James Blair and Donald Dougherty and Craig Ferris and Laurie Flynn and Evelyn Green and Kimberly Hoagwood and Janice Hutchinson and Tom Laughren and Leve, {Leslie D.} and Novins, {Douglas K.} and Benedetto Vitiello",
year = "2007",
month = "3",
day = "1",
doi = "10.1097/chi.0b013e31802f1454",
language = "English (US)",
volume = "46",
pages = "309--322",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "3",

}

Jensen, PS, Youngstrom, EA, Steiner, H, Findling, RL, Meyer, R, Malone, RP, Carlson, GA, Coccaro, EF, Aman, MG, Blair, J, Dougherty, D, Ferris, C, Flynn, L, Green, E, Hoagwood, K, Hutchinson, J, Laughren, T, Leve, LD, Novins, DK & Vitiello, B 2007, 'Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: Implications for medication studies', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 46, no. 3, pp. 309-322. https://doi.org/10.1097/chi.0b013e31802f1454

Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry : Implications for medication studies. / Jensen, Peter S.; Youngstrom, Eric A.; Steiner, Hans; Findling, Robert L.; Meyer, Roger; Malone, Richard P.; Carlson, Gabrielle A.; Coccaro, Emil F.; Aman, Michael G.; Blair, James; Dougherty, Donald; Ferris, Craig; Flynn, Laurie; Green, Evelyn; Hoagwood, Kimberly; Hutchinson, Janice; Laughren, Tom; Leve, Leslie D.; Novins, Douglas K.; Vitiello, Benedetto.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 46, No. 3, 01.03.2007, p. 309-322.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry

T2 - Implications for medication studies

AU - Jensen, Peter S.

AU - Youngstrom, Eric A.

AU - Steiner, Hans

AU - Findling, Robert L.

AU - Meyer, Roger

AU - Malone, Richard P.

AU - Carlson, Gabrielle A.

AU - Coccaro, Emil F.

AU - Aman, Michael G.

AU - Blair, James

AU - Dougherty, Donald

AU - Ferris, Craig

AU - Flynn, Laurie

AU - Green, Evelyn

AU - Hoagwood, Kimberly

AU - Hutchinson, Janice

AU - Laughren, Tom

AU - Leve, Leslie D.

AU - Novins, Douglas K.

AU - Vitiello, Benedetto

PY - 2007/3/1

Y1 - 2007/3/1

N2 - OBJECTIVE: To determine whether impulsive aggression (IA) is a meaningful clinical construct and to ascertain whether it is sufficiently similar across diagnostic categories, such that parallel studies across disorders might constitute appropriate evidence for pursuing indications. If so, how should IA be assessed, pharmacological studies designed, and ethical issues addressed? METHOD: Experts from key stakeholder communities, including academic clinicians, researchers, practicing clinicians, U.S. Food and Drug Administration, National Institute of Mental Health, industry sponsors, and patient and family advocates, met for a 2-day consensus conference on November 4 and 5, 2004. After evaluating summary presentations on current research evidence, participants were assigned to three workgroups, examined core issues, and generated consensus guidelines in their areas. Workgroup recommendations were discussed by the whole group to reach consensus, and then further iterated and condensed into this report postconference by the authors. RESULTS: Conference participants agreed that IA is a substantial public health and clinical concern, constitutes a key therapeutic target across multiple disorders, and can be measured with sufficient precision that pharmacological studies are warranted. Additional areas of consensus concerned types of measures, optimal study designs, and ethical imperatives. CONCLUSION: Derived from scientific evidence and clinical experience, these consensus-driven recommendations can guide the design of future studies. Copyright 2007

AB - OBJECTIVE: To determine whether impulsive aggression (IA) is a meaningful clinical construct and to ascertain whether it is sufficiently similar across diagnostic categories, such that parallel studies across disorders might constitute appropriate evidence for pursuing indications. If so, how should IA be assessed, pharmacological studies designed, and ethical issues addressed? METHOD: Experts from key stakeholder communities, including academic clinicians, researchers, practicing clinicians, U.S. Food and Drug Administration, National Institute of Mental Health, industry sponsors, and patient and family advocates, met for a 2-day consensus conference on November 4 and 5, 2004. After evaluating summary presentations on current research evidence, participants were assigned to three workgroups, examined core issues, and generated consensus guidelines in their areas. Workgroup recommendations were discussed by the whole group to reach consensus, and then further iterated and condensed into this report postconference by the authors. RESULTS: Conference participants agreed that IA is a substantial public health and clinical concern, constitutes a key therapeutic target across multiple disorders, and can be measured with sufficient precision that pharmacological studies are warranted. Additional areas of consensus concerned types of measures, optimal study designs, and ethical imperatives. CONCLUSION: Derived from scientific evidence and clinical experience, these consensus-driven recommendations can guide the design of future studies. Copyright 2007

UR - http://www.scopus.com/inward/record.url?scp=33847187345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847187345&partnerID=8YFLogxK

U2 - 10.1097/chi.0b013e31802f1454

DO - 10.1097/chi.0b013e31802f1454

M3 - Article

C2 - 17314717

AN - SCOPUS:33847187345

VL - 46

SP - 309

EP - 322

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 3

ER -